Completion of GMP ACU-0943 batch manufacture with Laurus

Aculeus is proud to announce the successful completion of its clinical trial batch manufacture of ACU-0943, a potent and selective small molecule STING agonist. This milestone was achieved in collaboration with Laurus Labs, based in India.

While current Good Manufacturing Practice (cGMP) compliance is not required for clinical trials conducted in Australia, Aculeus has chosen to adhere to these rigorous standards. This strategic decision enables the company to pursue both national and international clinical trial opportunities.